Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.

Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hänlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R

Lancet (London, England)1 Apr 1998Cited by 219 (Europe PMC)

PMID9643742DOI10.1016/s0140-6736(97)11329-0PepBankPUB-09643742

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with dilated cardiomyopathy, rhGH increased left-ventricular mass by 27% versus placebo (p=0.0001).
In plain wordsIn patients with dilated cardiomyopathy, rhGH increased left-ventricular mass by 27% compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseLeft-ventricular mass
Study
n = 50
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Measurements
Left-ventricular mass increase
27%
rhGH versus placebo
Source sentences
Summary
Patients in the rhGH group had an increase in left-ventricular mass compared with those in the placebo group (27%, p=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374201
02HumanRandomized controlled trialEfficacy outcome
In patients with dilated cardiomyopathy, rhGH did not significantly change left-ventricular systolic wall stress versus placebo.
In plain wordsIn patients with dilated cardiomyopathy, rhGH did not significantly change heart wall stress compared with placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeLeft-ventricular systolic wall stress
Study
n = 50
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Source sentences
Summary
There was no significant difference in left-ventricular systolic wall stress, mean blood pressure, or systemic vascular resistance between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374202
03HumanRandomized controlled trialEfficacy outcome
In patients with dilated cardiomyopathy, rhGH did not significantly change mean blood pressure versus placebo.
In plain wordsIn patients with dilated cardiomyopathy, rhGH did not significantly change mean blood pressure compared with placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeMean blood pressure
Study
n = 50
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Source sentences
Summary
There was no significant difference in left-ventricular systolic wall stress, mean blood pressure, or systemic vascular resistance between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374203
04HumanRandomized controlled trialEfficacy outcome
In patients with dilated cardiomyopathy, rhGH did not significantly change systemic vascular resistance versus placebo.
In plain wordsIn patients with dilated cardiomyopathy, rhGH did not significantly change blood vessel resistance compared with placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeSystemic vascular resistance
Study
n = 50
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Source sentences
Summary
There was no significant difference in left-ventricular systolic wall stress, mean blood pressure, or systemic vascular resistance between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374204
05HumanRandomized controlled trialEfficacy outcome
In patients with dilated cardiomyopathy, serum IGF-I changed by 77 ng/mL with rhGH versus -19 ng/mL with placebo (p=0.0001).
In plain wordsIn patients with dilated cardiomyopathy, blood IGF-I increased with rhGH compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum IGF-I change
Study
n = 50
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Measurements
Serum IGF-I change
77 ng/mL
rhGH
Serum IGF-I change
−19 ng/mL
placebo
Source sentences
Summary
The change in serum insulin-like growth factor (IGF)-I concentrations (rhGH 77 ng/mL; placebo -19 ng/mL, GH vs placebo p=0.0001) was significantly related to the change in left-ventricular mass (r=0.55, p=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374208
06HumanNon-randomized trialEfficacy outcome
In patients with dilated cardiomyopathy, left-ventricular ejection fraction was unchanged with rhGH.
In plain wordsIn patients with dilated cardiomyopathy, the heart's ejection fraction did not change with rhGH.
Peptide
HGH (somatotropin)
Outcome
No significant changeLeft-ventricular ejection fraction
Study
n = 50
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Source sentences
Summary
New York Heart Association functional class, left-ventricular ejection fraction, and distance on the 6 min walking test were unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374206
07HumanNon-randomized trialEfficacy outcome
In patients with dilated cardiomyopathy, NYHA functional class was unchanged with rhGH.
In plain wordsIn patients with dilated cardiomyopathy, the heart failure functional class did not change with rhGH.
Peptide
HGH (somatotropin)
Outcome
No significant changeNYHA functional class
Study
n = 50
Outcome group
Heart function · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Source sentences
Summary
New York Heart Association functional class, left-ventricular ejection fraction, and distance on the 6 min walking test were unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374205
08HumanNon-randomized trialEfficacy outcome
In patients with dilated cardiomyopathy, rhGH did not change distance on the 6 min walking test.
In plain wordsIn patients with dilated cardiomyopathy, walking distance on the 6 min test did not change with rhGH.
Peptide
HGH (somatotropin)
Outcome
No significant changeWalking distance
Study
n = 50
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Source sentences
Summary
New York Heart Association functional class, left-ventricular ejection fraction, and distance on the 6 min walking test were unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374207
09HumanNon-randomized trialSafety outcome
In patients with dilated cardiomyopathy, one rhGH recipient withdrew at 6 weeks because heart failure worsened.
In plain wordsIn patients with dilated cardiomyopathy, one rhGH recipient stopped treatment at 6 weeks because heart failure worsened.
Peptide
HGH (somatotropin)
Outcome
Not applicableWithdrawal for worsening heart failure
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Studied dose
2 IU daily · subcutaneous · 6 weeksAs given in this study (human).
Measurements
Patients withdrawn for worsening heart failure
1 patients
rhGH group, at 6 weeks
Source sentences
Summary
One patient in the rhGH group was withdrawn at 6 weeks because of worsening heart failure.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374210
10HumanObservational studyMechanism
In patients with dilated cardiomyopathy, IGF-I changes during rhGH treatment correlated with left-ventricular mass changes (r=0.55, p=0.0001).
In plain wordsIn patients with dilated cardiomyopathy, IGF-I changes during rhGH treatment correlated with changes in heart muscle mass.
Peptide
HGH (somatotropin)
Outcome
Not applicableIGF-I and left-ventricular mass association
Study
n = 50
Outcome group
Heart function · Cardiovascular
Studied dose
2 IU daily · subcutaneous · minimum of 12 weeksAs given in this study (human).
Measurements
Correlation coefficient (IGF-I change vs left-ventricular mass change)
0.55 r
patients in the trial
Source sentences
Summary
The change in serum insulin-like growth factor (IGF)-I concentrations (rhGH 77 ng/mL; placebo -19 ng/mL, GH vs placebo p=0.0001) was significantly related to the change in left-ventricular mass (r=0.55, p=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy.
Summary · context
50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks.
Report a problemFND-0964374209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.